Hjem › Blodkreft › Tennessee › Nashville
Kliniske studier for Blodkreft i Nashville, TN
13 studier for Blodkreft søker deltakere på steder i og rundt Nashville (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
RekruttererFase 3
- Vanderbilt Health One Hundred Oaks Diagnostic ( Site 0060), Nashville
- Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0015), Nashville
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
RekruttererFase 1
- Sarah Cannon Cancer Institute, Nashville
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RekruttererFase 3
- Quetzal Site 12, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekruttererFase 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RekruttererFase 3
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruttererFase 1
- Vanderbilt University Medical Center, Nashville
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
RekruttererFase 1
- Sarah Cannon Research Institute - Oncology Partners, Nashville
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RekruttererFase 2
- Vanderbilt University, Ingram Cancer Center, Nashville
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruttererObservasjonsstudie
- Vanderbilt University, Nashville
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
RekruttererFase 3
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
RekruttererFase 1
- TriStar Bone Marrow Transplant, Nashville
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
RekruttererFase 1/2
- SCRI Oncology Partners, Nashville
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RekruttererFase 1
- TriStar Bone Marrow Transplant, Nashville
Blodkreft-studier i andre byer
- Houston, TX46 studier
- New York City, NY26 studier
- Boston, MA25 studier
- Washington, DC19 studier
- Seattle, WA18 studier
- Baltimore, MD18 studier
- Los Angeles, CA17 studier
- Durham, NC16 studier
- Chicago, IL15 studier
- Philadelphia, PA14 studier
- Columbus, OH13 studier
- Edison, NJ13 studier
Andre studier i Nashville
- Ikke-småcellet lungekreft97 studier
- Brystkreft81 studier
- Metastatisk kreft70 studier
- Kolorektal kreft69 studier
- Kreft (alle typer)65 studier
- Eggstokkreft49 studier
- Prostatakreft43 studier
- Lungekreft40 studier
- Plateepitelcancer i hode og hals39 studier
- Pankreaskreft39 studier
- Endometriekreft38 studier
- Melanom33 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.